Posts

Posted on

Rocket Lab Successfully Launches First Batch of TROPICS Satellites for NASA

Rocket Lab Successfully Launches First Batch of TROPICS Satellites for NASA

The ‘Rocket Like a Hurricane’ launch was the first of two dedicated Electron launches to deploy a constellation of hurricane monitoring satellites for NASA

MAHIA, New Zealand–(BUSINESS WIRE)–
Rocket Lab USA, Inc. (Nasdaq: RKLB) (“Rocket Lab” or “the Company”), a leading launch and space systems company, today successfully completed the first of two dedicated Electron launches to deploy a constellation of tropical cyclone monitoring satellites for NASA.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230507005055/en/

Electron lifts off from Rocket Lab Launch Complex 1 for the 'Rocket Like a Hurricane' launch to deploy satellites for NASA's TROPICS constellation. (Photo: Business Wire)

Electron lifts off from Rocket Lab Launch Complex 1 for the ‘Rocket Like a Hurricane’ launch to deploy satellites for NASA’s TROPICS constellation. (Photo: Business Wire)

The ‘Rocket Like a Hurricane’ launch lifted-off on May 8 at 13:00 NZST (01:00 UTC) from Rocket Lab Launch Complex 1 on New Zealand’s Mahia Peninsula deploying two of the four CubeSats that comprise the TROPICS constellation (Time-Resolved Observations of Precipitation structure and storm Intensity with a Constellation of Smallsats). TROPICS will monitor the formation and evolution of tropical cyclones, including hurricanes, and will provide rapidly updating observations of storm intensity.

The constellation, which is part of NASA’s Earth System Science Pathfinder Program, requires launch to 550 kilometers altitude and inclination of about 30 degrees. Each pair of CubeSats must be launched to two specific orbital planes that are equally spaced 180 degrees opposite to maximize the temporal resolution. These unique orbits over Earth’s tropics allow the satellites to travel over any given storm about once an hour compared with current weather tracking satellites that have a timing of about once every six hours. This high revisit rate aims to help scientists better understand the processes that effect these high-impact storms, ultimately leading to improved modeling and prediction to help protect lives and livelihoods. All four TROPICS satellites need to be deployed into their operational orbit within a 60-day period, a mission requirement made possible with small dedicated launch. With the first batch of TROPICS CubeSats now in orbit, the second launch, called ‘Coming to a Storm Near You,’ is expected to launch on another Electron rocket in approximately two weeks from Launch Complex 1.

“The TROPICS constellation has the real potential to save lives by providing more timely data about storm intensity and providing advance warning to those in storm paths, so it’s an immense privilege to have deployed these spacecraft to their precise orbits before the upcoming storm season,” said Rocket Lab founder and CEO Peter Beck. “We’re grateful to the NASA team for entrusting us with such a critical mission and we look forward to completing the constellation with the second Electron launch in the coming days.”

“We are extremely proud of all our partners, including MIT Lincoln Labs, Blue Canyon Technologies, KSAT, and Rocket Lab for successfully executing on this first launch. We look forward to the entire constellation being on-orbit to realize the benefits for the agency, as well as for our colleagues around the world,” said Ben Kim, TROPICS program executive for NASA’s Earth Science Division.

‘Rocket Like a Hurricane’ was Rocket Lab’s fourth mission for 2023 and the Company’s 36th Electron mission overall. It brings the total number of satellites launched to orbit by Rocket Lab to 161.

Follow Rocket Lab on Twitter @RocketLab for real-time updates about the next TROPICS launch.

ABOUT Rocket Lab

Founded in 2006, Rocket Lab is an end-to-end space company with an established track record of mission success. We deliver reliable launch services, satellite manufacture, spacecraft components, and on-orbit management solutions that make it faster, easier and more affordable to access space. Headquartered in Long Beach, California, Rocket Lab designs and manufactures the Electron small orbital launch vehicle, the Photon satellite platform and the Company is developing the large Neutron launch vehicle for constellation deployment. Since its first orbital launch in January 2018, Rocket Lab’s Electron launch vehicle has become the second most frequently launched U.S. rocket annually and has delivered 161 satellites to orbit for private and public sector organizations, enabling operations in national security, scientific research, space debris mitigation, Earth observation, climate monitoring, and communications. Rocket Lab’s Photon spacecraft platform has been selected to support NASA missions to the Moon and Mars, as well as the first private commercial mission to Venus. Rocket Lab has three launch pads at two launch sites, including two launch pads at a private orbital launch site located in New Zealand and a third pad in Virginia. To learn more, visit www.rocketlabusa.com.

Forward-Looking Statements

This press release may contain certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, contained in this release, including statements regarding our expectations of financial results for first quarter 2023, strategy, future operations, future financial position, projected costs, prospects, plans and objectives of management, are forward-looking statements. Words such as, but not limited to, “anticipate,” “aim,” “believe,” “contemplate,” “continue,” “could,” “design,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “seek,” “should,” “suggest,” “strategy,” “target,” “will,” “would,” and similar expressions or phrases, or the negative of those expressions or phrases, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements are based on Rocket Lab’s current expectations and beliefs concerning future developments and their potential effects. These forward-looking statements involve a number of risks, uncertainties (many of which are beyond Rocket Lab’s control), or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including risks related to the global COVID-19 pandemic; risks related to government restrictions and lock-downs in New Zealand and other countries in which we operate that could delay or suspend our operations; delays and disruptions in expansion efforts; our dependence on a limited number of customers; the harsh and unpredictable environment of space in which our products operate which could adversely affect our launch vehicle and spacecraft; increased congestion from the proliferation of low Earth orbit constellations which could materially increase the risk of potential collision with space debris or another spacecraft and limit or impair our launch flexibility and/or access to our own orbital slots; increased competition in our industry due in part to rapid technological development and decreasing costs; technological change in our industry which we may not be able to keep up with or which may render our services uncompetitive; average selling price trends; failure of our launch vehicles, spacecraft and components to operate as intended either due to our error in design in production or through no fault of our own; launch schedule disruptions; supply chain disruptions, product delays or failures; design and engineering flaws; launch failures; natural disasters and epidemics or pandemics; changes in governmental regulations including with respect to trade and export restrictions, or in the status of our regulatory approvals or applications; or other events that force us to cancel or reschedule launches, including customer contractual rescheduling and termination rights; risks that acquisitions may not be completed on the anticipated time frame or at all or do not achieve the anticipated benefits and results; and the other risks detailed from time to time in Rocket Lab’s filings with the Securities and Exchange Commission (the “SEC”), including under the heading “Risk Factors” in Rocket Lab’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, which was filed with the SEC on March 7, 2023, and elsewhere (including that the impact of the COVID-19 pandemic may also exacerbate the risks discussed therein). There can be no assurance that the future developments affecting Rocket Lab will be those that we have anticipated. Except as required by law, Rocket Lab is not undertaking any obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Rocket Lab Media Contact

Morgan Bailey

[email protected]

KEYWORDS: California Australia/Oceania New Zealand United States North America

INDUSTRY KEYWORDS: Technology Research Satellite Other Technology Aerospace Manufacturing Hardware Other Science Science

MEDIA:

Logo
Logo
Photo
Photo
Electron lifts off from Rocket Lab Launch Complex 1 for the ‘Rocket Like a Hurricane’ launch to deploy satellites for NASA’s TROPICS constellation. (Photo: Business Wire)
Posted on

SomaLogic opens their first-ever proteomics grant program to APAC life sciences researchers

Two winners will be awarded 40 human plasma or serum samples to be processed on the SomaScan

®

Platform at Genomax’s Singapore lab

SINGAPORE & BOULDER, Colo., May 07, 2023 (GLOBE NEWSWIRE) — SomaLogic, Inc., a global leader in proteomics technology, today announced that it is sponsoring the Genomax Research Grant Award for researchers in Singapore. This effort is SomaLogic’s first grant in the APAC region. The winners of the award will receive proteomic data from SomaLogic’s 7,000-plex assay, which will be run at Singapore-based Molecular Genomics, a Genomax Technologies company. The Genomax site, opened in November 2022, was the first SomaLogic authorized site in Asia to offer the SomaScan® Platform.

The grant program, which was launched at the Asia Oceana Human Proteome Organisation (AOHUPO) meeting in Singapore, requires that researchers in academic, medical centers, pharmaceutical companies, and contract research organizations in life sciences, submit a proposal outlining how they will use the SomaScan Platform to expand their research goals in health or in a specific disease area. Two winners will be awarded 40 human plasma or serum samples to be processed on the SomaScan Platform at Genomax’s Singapore lab. Researchers can apply on SomaLogic’s website: http://somalogic.com/genomaxgrant2023.

While experts across the region have long embraced the value of genomics, life science researchers in Asia are now increasingly appreciating the power and the promise of proteomics in their discovery efforts. SomaLogic’s proprietary protein detection and analysis technology measures how proteins function and interact, supporting researchers in drug research and development, and biomarker identification efforts.

“Asia is an incredibly important and rapidly growing market because of their increasing focus on translational work in life sciences and clinical research,” said SomaLogic Chief Executive Officer Adam Taich. “We are excited to bring this inaugural grant program to researchers in Singapore who can advance their studies through our partnership with Molecular Genomics, which has been accelerating biodiscovery in Southeast Asia for more than a decade.”

About SomaLogic 

SomaLogic is catalyzing drug research and development and biomarker identification as a global leader in proteomics technology. With a single 55 microliter plasma or serum sample, SomaLogic can run 7,000 protein measurements, covering more than a third of the approximately 20,000 proteins in the human body and twice as many as other proteomic platforms. For more than 20 years we’ve supported pharmaceutical companies, and academic and contract research organizations who rely on our protein detection and analysis technologies to fuel drug, disease, and treatment discoveries in such areas as oncology, diabetes, and cardiovascular, liver and metabolic diseases. Find out more at www.somalogic.com and follow @somalogic on LinkedIn.

Forward Looking Statements Disclaimer 
This press release contains certain forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements, other than statements of historical fact included in this press release, regarding our strategy, future operations, financial position, estimated revenues, projections, prospects, plans and objectives of management are forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “forecast,” “guidance,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “continue,” “will likely result,” “possible,” “potential,” “predict,” “pursue,” “target” and similar expressions, although not all forward-looking statements contain such identifying words. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Forward-looking statements do not guarantee future performance and involve known and unknown risks, uncertainties and other factors. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including factors which are beyond SomaLogic’s control. You should carefully consider these risks and uncertainties, including, but not limited to, those factors described under Part I, Item 1A – “Risk Factors” in our Annual Report on Form 10-K and other filings we make with the Securities and Exchange Commission. These filings identify and address important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and SomaLogic assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Should one or more of these risks or uncertainties materialize, or should any of the assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. The Company will not and does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. 

Media Contact

Emilia Costales
720-798-5054
[email protected]

Investor Contacts

Lauren Glaser 
[email protected] 



Posted on

Henry Schein Acquires Regional Health Care Group, a Medical Distributor Serving the Australia and New Zealand Region

Henry Schein Acquires Regional Health Care Group, a Medical Distributor Serving the Australia and New Zealand Region

MELVILLE, N.Y.–(BUSINESS WIRE)–
Henry Schein, Inc. (Nasdaq: HSIC), the world’s largest provider of health care products and services to office-based dental and medical practitioners, announced today the acquisition of Regional Health Care Group Pty Ltd (RHCG), a medical products distribution company serving public- and private-sector customers in Australia and New Zealand.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230505005288/en/

Since 1998, Henry Schein has served the Australian and New Zealand dental market, providing a wide range of dental products, equipment, and services to dental professionals. The addition of RHCG expands Henry Schein’s offering to medical practitioners in the region.

Henry Schein acquired RHCG, which had sales for the 12 months ended June 30, 2022, of $42 million, from Maurie and Bernard Stang, who wholly owned the company and retain a minority interest in Henry Schein’s ANZ dental business. Henry Schein expects the transaction to be neutral to 2023 diluted earnings per share when excluding amortization expenses and accretive thereafter. Financial terms were not disclosed.

“We are pleased to welcome the Regional Health Care Group to Henry Schein,” said Stanley M. Bergman, Chairman of the Board and Chief Executive Officer of Henry Schein. “Together, we will advance our long-standing goal of helping health care professionals operate more efficient practices by providing new solutions and technologies for the ultimate benefit of patients.”

Headquartered in Sydney, Australia, with an office in Auckland, New Zealand, RHCG offers a wide range of consumables, equipment, and pharmaceuticals – including many on an exclusive or semi-exclusive basis – primarily to public- and private-sector customers. The day-to-day operations of RHCG are led by General Manager Stephen Doorey, who will continue to manage the business under the highly regarded Regional Health Care Group brand. Mr. Doorey will report to Mike Covey, Vice President and Managing Director of Henry Schein’s business in Australia and New Zealand.

“We are very pleased to integrate RHCG with Henry Schein, a company that shares our commitment to excellent service and provides customers with the solutions they need to deliver quality care to their patients,” said Maurie Stang. “It’s extremely gratifying to see the exciting opportunities to accelerate our growth.”

About Henry Schein, Inc.

Henry Schein, Inc. (Nasdaq: HSIC) is a solutions company for health care professionals powered by a network of people and technology. With more than 22,000 Team Schein Members worldwide, the Company’s network of trusted advisors provides more than 1 million customers globally with more than 300 valued solutions that help improve operational success and clinical outcomes. Our Business, Clinical, Technology, and Supply Chain solutions help office-based dental and medical practitioners work more efficiently so they can provide quality care more effectively. These solutions also support dental laboratories, government and institutional health care clinics, as well as other alternate care sites.

Henry Schein operates through a centralized and automated distribution network, with a selection of more than 300,000 branded products and Henry Schein private-brand products in stock.

A FORTUNE 500 Company and a member of the S&P 500® index, Henry Schein is headquartered in Melville, N.Y., and has operations or affiliates in 32 countries and territories. The Company’s sales reached $12.6 billion in 2022, and have grown at a compound annual rate of approximately 12.1 percent since Henry Schein became a public company in 1995.

For more information, visit Henry Schein at www.henryschein.com, Facebook.com/HenrySchein, Instagram.com/HenrySchein, and Twitter.com/HenrySchein.

Cautionary Note Regarding Forward-Looking Statements

In accordance with the “Safe Harbor” provisions of the Private Securities Litigation Reform Act of 1995, we provide the following cautionary remarks regarding important factors that, among others, could cause future results to differ materially from the forward-looking statements, expectations and assumptions expressed or implied herein. All forward-looking statements made by us are subject to risks and uncertainties and are not guarantees of future performance. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance and achievements or industry results to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. These statements include EPS guidance and are generally identified by the use of such terms as “may,” “could,” “expect,” “intend,” “believe,” “plan,” “estimate,” “forecast,” “project,” “anticipate,” “to be,” “to make” or other comparable terms. A fuller discussion of our operations, financial condition and status of litigation matters, including factors that may affect our business and future prospects, is contained in documents we have filed with the United States Securities and Exchange Commission, or SEC, including our Annual Report on Form 10-K, and will be contained in all subsequent periodic filings we make with the SEC. These documents identify in detail important risk factors that could cause our actual performance to differ materially from current expectations. Forward looking statements include the overall impact of the Novel Coronavirus Disease 2019 (COVID-19) on the Company, its results of operations, liquidity and financial condition (including any estimates of the impact on these items), the rate and consistency with which dental and other practices resume or maintain normal operations in the United States and internationally, expectations regarding personal protective equipment (“PPE”) and COVID-19 related product sales and inventory levels, whether additional resurgences or variants of the virus will adversely impact the resumption of normal operations, whether supply chain disruptions will adversely impact our business, the impact of integration and restructuring programs as well as of any future acquisitions, general economic conditions including exchange rates, inflation and recession, and more generally current expectations regarding performance in current and future periods. Forward looking statements also include the (i) ability of the Company to have continued access to a variety of COVID-19 test types, expectations regarding COVID-19 test sales, demand and inventory levels, as well as the efficacy or relative efficacy of the test results given that the test efficacy has not been, or will not have been, independently verified under normal FDA procedures, and (ii) potential for the Company to distribute the COVID-19 vaccines and ancillary supplies.

Risk factors and uncertainties that could cause actual results to differ materially from current and historical results include, but are not limited to: risks associated with COVID-19 and any variants thereof, as well as other disease outbreaks, epidemics, pandemics, or similar wide-spread public health concerns and other natural disasters; our dependence on third parties for the manufacture and supply of our products; our ability to develop or acquire and maintain and protect new products (particularly technology products) and technologies that achieve market acceptance with acceptable margins; transitional challenges associated with acquisitions, dispositions and joint ventures, including the failure to achieve anticipated synergies/benefits; financial and tax risks associated with acquisitions, dispositions and joint ventures; certain provisions in our governing documents that may discourage third-party acquisitions of us; effects of a highly competitive (including, without limitation, competition from third-party online commerce sites) and consolidating market; the repeal or judicial prohibition on implementation of the Affordable Care Act; changes in the health care industry; risks from expansion of customer purchasing power and multi-tiered costing structures; increases in shipping costs for our products or other service issues with our third-party shippers; general global and domestic macroeconomic and political conditions, including inflation, deflation, recession, fluctuations in energy pricing and the value of the U.S. dollar as compared to foreign currencies and changes to other economic indicators, international trade agreements, potential trade barriers and terrorism; failure to comply with existing and future regulatory requirements; risks associated with the EU Medical Device Regulation; failure to comply with laws and regulations relating to health care fraud or other laws and regulations; failure to comply with laws and regulations relating to the collection, storage and processing of sensitive personal information or standards in electronic health records or transmissions; changes in tax legislation; risks related to product liability, intellectual property and other claims; litigation risks; new or unanticipated litigation developments and the status of litigation matters; risks associated with customs policies or legislative import restrictions; cyberattacks or other privacy or data security breaches; risks associated with our global operations; our dependence on our senior management, employee hiring and retention, and our relationships with customers, suppliers and manufacturers; and disruptions in financial markets. The order in which these factors appear should not be construed to indicate their relative importance or priority.

We caution that these factors may not be exhaustive and that many of these factors are beyond our ability to control or predict. Accordingly, any forward-looking statements contained herein should not be relied upon as a prediction of actual results. We undertake no duty and have no obligation to update forward-looking statements except as required by law.

Investors

Ronald N. South

Senior Vice President and Chief Financial Officer

[email protected]

(631) 843-5500

Graham Stanley

Vice President, Investor Relations and Strategic Financial Project Officer

[email protected]

(631) 843-5500

Media

Ann Marie Gothard

Vice President, Global Corporate Media Relations

[email protected]

(631) 390-8169

KEYWORDS: New York North America United States Australia Australia/Oceania New Zealand

INDUSTRY KEYWORDS: Medical Supplies Health Practice Management Dental Managed Care General Health

MEDIA:

Logo
Logo
Logo
Logo
Posted on

Exelixis Announces Departure of Lance Willsey, M.D. From Board of Directors

Exelixis Announces Departure of Lance Willsey, M.D. From Board of Directors

ALAMEDA, Calif.–(BUSINESS WIRE)–Exelixis, Inc. (Nasdaq: EXEL) (the “Company”) today announced that Lance Willsey, M.D. has informed the Board of Directors of his decision to resign from the Board, effective immediately. The Board recommends shareholders vote in favor of its remaining 10 director nominees and will not contest the election of Farallon Capital Management’s (“Farallon”) additional nominee, David Johnson, at the upcoming 2023 Annual Meeting of Shareholders, to be held on May 31, 2023.

As previously announced, the Board nominated two of Farallon’s originally proposed candidates – Tomas Heyman and Robert Oliver – to replace two of its existing directors at the Annual Meeting. The Board is actively identifying, evaluating and interviewing candidates as part of its continued refreshment program, which includes a commitment to replacing two additional directors, one in each of the next two years, with two new independent directors. Following the upcoming Annual Meeting, five directors will have transitioned off the Board in the past three years, and four new independent directors will have been elected, including all of Farallon’s nominees.

The Board supports Dr. Willsey’s decision, which will end the need for Farallon to continue its proxy campaign. The Company is focused on advancing its mission to develop life-changing cancer therapies and build long-term shareholder value. Dr. Willsey’s decision to resign is in connection with a personal matter that occurred more than a decade ago. The Company engaged outside legal counsel at that time to review the matter and the Board at the time decided that no action was needed with respect to Dr. Willsey’s Board representation.

About Exelixis

Exelixis is a globally ambitious oncology company innovating next-generation medicines and regimens at the forefront of cancer care. Powered by bi-coastal centers of discovery and development excellence, we are rapidly evolving our product portfolio to target an expanding range of tumor types and indications with our clinically differentiated pipeline of small molecules, antibody-drug conjugates and other biotherapeutics. This comprehensive approach harnesses decades of robust investment in our science and partnerships to advance our investigational programs and extend the impact of our flagship commercial product, CABOMETYX® (cabozantinib). Exelixis is driven by a bold scientific pursuit to create transformational treatments that give more patients hope for the future. For information about the company and its mission to help cancer patients recover stronger and live longer, visit www.exelixis.com, follow @ExelixisInc on Twitter, like Exelixis, Inc. on Facebook and follow Exelixis on LinkedIn.

Exelixis Forward-Looking Statements

This document contains forward-looking statements. Any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements and are based upon Exelixis’ current plans, assumptions, beliefs, expectations, estimates and projections. Forward-looking statements involve risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in the forward-looking statements as a result of these risks and uncertainties, which include, without limitation the factors affecting Exelixis discussed under the caption “Risk Factors” in Exelixis’ Annual Report on Form 10-K filed with the SEC on February 7, 2023, and in Exelixis’ future filings with the SEC. All forward-looking statements in this document are based on information available to Exelixis as of the date of this document, and Exelixis undertakes no obligation to update or revise any forward-looking statements contained herein, except as required by law.

Important Information Regarding the GOLD Proxy Card

Exelixis does not intend to circulate an updated GOLD proxy card as a result of Dr. Lance Willsey’s resignation from the Board of Directors. The persons named as proxies in the GOLD proxy card will vote the relevant shares of Exelixis common stock at the 2023 Annual Meeting as indicated on such proxy card with respect to each of the remaining nominees recommended by the Exelixis Board of Directors (the “Board Recommended Nominees”). However, no votes will be cast for Dr. Willsey. If any GOLD proxy card is submitted with no voting instructions, the relevant shares will be voted “FOR” each of the remaining Board Recommended Nominees and no votes will be cast for Dr. Willsey.

Important Stockholder Information

Exelixis has filed a definitive proxy statement, containing a form of GOLD proxy card, with the SEC in connection with its solicitation of proxies for its 2023 Annual Meeting. THE COMPANY’S SHAREHOLDERS ARE STRONGLY ENCOURAGED TO READ THE DEFINITIVE PROXY STATEMENT (AND ANY AMENDMENTS AND SUPPLEMENTS THERETO) AND ACCOMPANYING GOLD PROXY CARD AS THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION. Shareholders may obtain a copy of the definitive proxy statement, any amendments or supplements to the proxy statement and other documents filed by the Company with the SEC without charge from the SEC’s website at www.sec.gov.

The Company, its Directors and certain of its executive officers may be deemed to be participants in connection with the solicitation of proxies from the Company’s shareholders in connection with the matters to be considered at the 2023 Annual Meeting. Information regarding the ownership of the Company’s Directors and executive officers in the definitive proxy statement for its 2023 Annual Meeting, filed with the SEC on May 1, 2023, can be found through the SEC’s website at www.sec.gov. Changes to such ownership have been or will be reflected on Statements of Changes in Beneficial Ownership on Form 4 filed with the SEC. Details concerning the nominees of the Exelixis’ Board of Directors for election at the 2023 Annual Meeting are also included in such definitive proxy statement. These documents can be obtained free of charge from the sources indicated above.

Investor Contacts

Chris Senner

Chief Financial Officer

Exelixis, Inc.

650-837-7240

[email protected]

Susan Hubbard

EVP, Public Affairs & Investor Relations

Exelixis, Inc.

650-837-8194

[email protected]

Media Contacts

Jamie Moser / Sharon Stern / Tali Epstein

Joele Frank, Wilkinson Brimmer Katcher

212-355-4449

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Biotechnology Health Pharmaceutical Clinical Trials Oncology

MEDIA:

Logo
Logo
Posted on

Rocket Lab Prepares for First of Two Launches to Deploy Storm Monitoring Constellation for NASA

Rocket Lab Prepares for First of Two Launches to Deploy Storm Monitoring Constellation for NASA

The ‘Rocket Like a Hurricane’ launch is scheduled to lift off from Rocket Lab Launch Complex 1 in New Zealand as early as May 8 to deploy the first set of TROPICS satellites for NASA’s hurricane monitoring constellation

MAHIA, New Zealand–(BUSINESS WIRE)–
Rocket Lab USA, Inc. (Nasdaq: RKLB) (“Rocket Lab” or “the Company”), a leading launch and space systems company, is preparing for the first of two dedicated Electron launches to deploy a constellation of storm monitoring satellites for NASA.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230506005008/en/

Rocket Lab's Electron rocket on the pad at Launch Complex 1 in New Zealand ahead of the 'Rocket Like a Hurricane' launch, the first of two dedicated Electron launches for NASA to deploy the TROPICS storm-monitoring constellation. (Photo: Business Wire)

Rocket Lab’s Electron rocket on the pad at Launch Complex 1 in New Zealand ahead of the ‘Rocket Like a Hurricane’ launch, the first of two dedicated Electron launches for NASA to deploy the TROPICS storm-monitoring constellation. (Photo: Business Wire)

The first launch, called ‘Rocket Like a Hurricane,’ is scheduled for lift-off no earlier than 13:00 on May 8th NZST from Launch Complex 1 on New Zealand’s Mahia Peninsula. The launch window extends for two hours and there are back up opportunities throughout May should the launch date need to be adjusted.

Launch Window:

NZST: 13:00 – 15:00, May 8

UTC: 01:00 – 03:00, May 8

EDT: 21:00 – 23:00, May 7

PDT: 18:00 – 20:00, May 7

The TROPICS constellation (Time-Resolved Observations of Precipitation structure and storm Intensity with a Constellation of Smallsats) will monitor the formation and evolution of tropical cyclones, including hurricanes, and will provide rapidly updating observations of storm intensity. This data will help scientists better understand the processes that effect these high-impact storms, ultimately leading to improved modelling and prediction. The constellation, which is part of NASA’s Earth System Science Pathfinder Program, consists of four CubeSats that require launch to a specific orbit at an altitude of 550 kilometers and inclination of about 30 degrees. All four satellites need to be deployed into their operational orbit within a 60-day period. The second launch ‘Coming To a Storm Near You’ is expected to launch approximately two weeks following the successful launch of “Rocket Like a Hurricane.”

The live launch webcast will be available at www.rocketlabusa.com/live-stream from around T-20 minutes on launch day. Follow Rocket Lab on Twitter @RocketLab for real time mission updates on launch day.

“Electron has been providing reliable and dedicated launch for NASA since 2018, including a successful mission to the Moon last year, and it’s an honor to be entrusted once again for the TROPICS launches,” said Rocket Lab founder and CEO Peter Beck. “We’re immensely grateful to play a role in equipping scientists and researchers with more accurate and timely data about the formation and intensity of tropical storms to help protect lives and livelihoods.”

‘Rocket Like a Hurricane’ will be Rocket Lab’s fourth Electron mission for 2023 and the Company’s 36th launch overall since Rocket Lab’s first Electron launch in 2017. The TROPICS launches follow on from previous successful Electron missions for NASA, including the ELaNa-19 mission and CAPSTONE mission to the Moon.

ABOUT Rocket Lab

Founded in 2006, Rocket Lab is an end-to-end space company with an established track record of mission success. We deliver reliable launch services, satellite manufacture, spacecraft components, and on-orbit management solutions that make it faster, easier and more affordable to access space. Headquartered in Long Beach, California, Rocket Lab designs and manufactures the Electron small orbital launch vehicle, the Photon satellite platform and the Company is developing the large Neutron launch vehicle for constellation deployment. Since its first orbital launch in January 2018, Rocket Lab’s Electron launch vehicle has become the second most frequently launched U.S. rocket annually and has delivered 159 satellites to orbit for private and public sector organizations, enabling operations in national security, scientific research, space debris mitigation, Earth observation, climate monitoring, and communications. Rocket Lab’s Photon spacecraft platform has been selected to support NASA missions to the Moon and Mars, as well as the first private commercial mission to Venus. Rocket Lab has three launch pads at two launch sites, including two launch pads at a private orbital launch site located in New Zealand and a third pad in Virginia. To learn more, visit www.rocketlabusa.com.

Forward Looking Statements

This press release may contain certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, contained in this release, including statements regarding our expectations of financial results for first quarter 2023, strategy, future operations, future financial position, projected costs, prospects, plans and objectives of management, are forward-looking statements. Words such as, but not limited to, “anticipate,” “aim,” “believe,” “contemplate,” “continue,” “could,” “design,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “seek,” “should,” “suggest,” “strategy,” “target,” “will,” “would,” and similar expressions or phrases, or the negative of those expressions or phrases, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements are based on Rocket Lab’s current expectations and beliefs concerning future developments and their potential effects. These forward-looking statements involve a number of risks, uncertainties (many of which are beyond Rocket Lab’s control), or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including risks related to the global COVID-19 pandemic; risks related to government restrictions and lock-downs in New Zealand and other countries in which we operate that could delay or suspend our operations; delays and disruptions in expansion efforts; our dependence on a limited number of customers; the harsh and unpredictable environment of space in which our products operate which could adversely affect our launch vehicle and spacecraft; increased congestion from the proliferation of low Earth orbit constellations which could materially increase the risk of potential collision with space debris or another spacecraft and limit or impair our launch flexibility and/or access to our own orbital slots; increased competition in our industry due in part to rapid technological development and decreasing costs; technological change in our industry which we may not be able to keep up with or which may render our services uncompetitive; average selling price trends; failure of our launch vehicles, spacecraft and components to operate as intended either due to our error in design in production or through no fault of our own; launch schedule disruptions; supply chain disruptions, product delays or failures; design and engineering flaws; launch failures; natural disasters and epidemics or pandemics; changes in governmental regulations including with respect to trade and export restrictions, or in the status of our regulatory approvals or applications; or other events that force us to cancel or reschedule launches, including customer contractual rescheduling and termination rights; risks that acquisitions may not be completed on the anticipated time frame or at all or do not achieve the anticipated benefits and results; and the other risks detailed from time to time in Rocket Lab’s filings with the Securities and Exchange Commission (the “SEC”), including under the heading “Risk Factors” in Rocket Lab’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, which was filed with the SEC on March 7, 2023, and elsewhere (including that the impact of the COVID-19 pandemic may also exacerbate the risks discussed therein). There can be no assurance that the future developments affecting Rocket Lab will be those that we have anticipated. Except as required by law, Rocket Lab is not undertaking any obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Rocket Lab Media Contact

Morgan Bailey

[email protected]

KEYWORDS: California Australia/Oceania New Zealand United States North America

INDUSTRY KEYWORDS: Engineering Technology Satellite Aerospace Manufacturing Software

MEDIA:

Logo
Logo
Photo
Photo
Rocket Lab’s Electron rocket on the pad at Launch Complex 1 in New Zealand ahead of the ‘Rocket Like a Hurricane’ launch, the first of two dedicated Electron launches for NASA to deploy the TROPICS storm-monitoring constellation. (Photo: Business Wire)
Posted on

Mage Wins the 149th Running of the Kentucky Derby Presented by Woodford Reserve


149th Kentucky Derby Race, the Kentucky Derby Day Program, and Kentucky Derby Week Races All Set New Handle Records

LOUISVILLE, Ky., May 06, 2023 (GLOBE NEWSWIRE) — Churchill Downs Incorporated (“CDI”) (Nasdaq: CHDN) announced today that a spirited and vibrant crowd of 150,335 Derby fans at Churchill Downs Racetrack (“Churchill Downs”) witnessed Mage claim the Garland of Roses at the 149th running of the Kentucky Derby presented by Woodford Reserve at 15-1 odds under mostly sunny skies. CDI also announced that wagering from all sources was the highest all-time on the Kentucky Derby race, the Kentucky Derby Day program, and Kentucky Derby Week races.

Mage, owned by OGMA Investments, LLC (Gustavo Delgado), Ramiro Restrepo, Sterling Racing (Sam Herzberg) and Commonwealth Thoroughbred LLC (Brian Doxtator and Chase Chamberlin), bred in Kentucky by Grandview Equine (Robert Clay), trained by Gustavo Delgado, and ridden by Javier Castellano, rallied to win by a length. Mage covered the mile and a quarter in 2.01.57 over a fast track.

Wagering from all sources on the Kentucky Derby Day program set a new record of $288.7 million, beating last year’s record of $273.8 million. All-sources wagering on the Kentucky Derby race was a new record of $188.7 million, beating the previous record of $179.0 million set in 2022. All-sources handle for Derby Week rose to a new record of $412.0 million, beating last year’s record of $391.8 million.

TwinSpires, the official betting partner of the Kentucky Derby, handled a new record of $73.6 million in wagering on Churchill Downs races for the Kentucky Derby Day program, compared to last year’s record of $67.4 million. TwinSpires’ handle on the Kentucky Derby race was a new record of $47.0 million, beating last year’s record of $44.0 million.

“We were thrilled to debut our new First Turn Experience, a one-of-a-kind premium accommodation with exclusive views of the horses and the racetrack from the rail of the first turn, as we commemorated the 50th anniversary of Secretariat’s victory in the Run for the Roses,” said Bill Carstanjen, CEO of CDI. “We expect the Kentucky Derby Week Adjusted EBITDA to reflect a new record with $14 to $16 million of growth over the prior record set last year. We will now accelerate our focus on our year-long celebration in preparation for the 150th Kentucky Derby in May 2024.”

Use of Non-GAAP Measures

In addition to the results provided in accordance with GAAP, the Company also uses non-GAAP measures, including adjusted net income, adjusted diluted EPS, EBITDA (earnings before interest, taxes, depreciation and amortization), and Adjusted EBITDA.

The Company uses non-GAAP measures as a key performance measure of the results of operations for purposes of evaluating performance internally. These measures facilitate comparison of operating performance between periods and help investors to better understand the operating results of the Company by excluding certain items that may not be indicative of the Company’s core business or operating results. The Company believes the use of these measures enables management and investors to evaluate and compare, from period to period, the Company’s operating performance in a meaningful and consistent manner. The non-GAAP measures are a supplemental measure of our performance that is not required by, or presented in accordance with, GAAP, and should not be considered as an alternative to, or more meaningful than, net income or diluted EPS (as determined in accordance with GAAP) as a measure of our operating results.

We use Adjusted EBITDA to evaluate segment performance, develop strategy, and allocate resources. We utilize the Adjusted EBITDA metric to provide a more accurate measure of our core operating results and enable management and investors to evaluate and compare from period to period our operating performance in a meaningful and consistent manner. Adjusted EBITDA should not be considered as an alternative to operating income as an indicator of performance, as an alternative to cash flows from operating activities as a measure of liquidity, or as an alternative to any other measure provided in accordance with GAAP. Our calculation of Adjusted EBITDA may be different from the calculation used by other companies and, therefore, comparability may be limited.

Adjusted net income and adjusted diluted EPS exclude discontinued operations net income or loss; net income or loss attributable to noncontrolling interest; changes in fair value for interest rate swaps related to Rivers Des Plaines; Rivers Des Plaines’ legal reserves and transaction costs; transaction expense, which includes acquisition and disposition related charges, as well as legal, accounting, and other deal-related expense; pre-opening expense; and certain other gains, charges, recoveries, and expenses.

Adjusted EBITDA includes our portion of EBITDA from our equity investments.

Adjusted EBITDA excludes:

  • Transaction expense, net which includes:
    • Acquisition, disposition, and land sale related charges;
    • Direct online Sports and Casino business exit costs; and
    • Other transaction expense, including legal, accounting, and other deal-related expense;
  • Stock-based compensation expense;
  • Rivers Des Plaines’ impact on our investments in unconsolidated affiliates from:
    • The impact of changes in fair value of interest rate swaps; and
    • Legal reserves and transaction costs;
  • Asset impairments;
  • Gain on property sales;
  • Legal reserves;
  • Pre-opening expense; and
  • Other charges, recoveries, and expenses

As of December 31, 2021, Arlington ceased racing and simulcast operations and the property was sold on February 15, 2023 to the Chicago Bears. Arlington’s results in 2022 and 2023 are treated as an adjustment to EBITDA and are included in Other expenses, net in the Reconciliation of Comprehensive Income to Adjusted EBITDA.

About Churchill Downs Incorporated

Churchill Downs Incorporated (NASDAQ: CHDN) has been creating extraordinary entertainment experiences for nearly 150 years, beginning with the company’s most iconic and enduring asset, the Kentucky Derby. Headquartered in Louisville, Kentucky, CDI has expanded through the development of live and historical racing entertainment venues, the growth of the TwinSpires horse racing online wagering business and the operation and development of regional casino gaming properties. More information is available at http://www.churchilldownsincorporated.com.

This news release contains various “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are typically identified by the use of terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “predict,” “project,” “seek,” “should,” “will,” and similar words or similar expressions (or negative versions of such words or expressions).

Although we believe that the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. Important factors, among others, that may materially affect actual results or outcomes include the following: the occurrence of extraordinary events, such as terrorist attacks, public health threats, civil unrest, and inclement weather, including as a result of climate change; the effect of economic conditions on our consumers’ confidence and discretionary spending or our access to credit, including the impact of inflation; additional or increased taxes and fees; the impact of the novel coronavirus (COVID-19) pandemic, including the emergence of variant strains, and related economic matters on our results of operations, financial conditions and prospects; lack of confidence in the integrity of our core businesses or any deterioration in our reputation; loss of key or highly skilled personnel, as well as disruptions in the general labor market; the impact of significant competition, and the expectation the competition levels will increase; changes in consumer preferences, attendance, wagering, and sponsorships; risks associated with equity investments, strategic alliances and other third-party agreements; inability to respond to rapid technological changes in a timely manner; concentration and evolution of slot machine and historical racing machine (HRM) manufacturing or other technology conditions that could impose additional costs; failure to enter into or maintain agreements with industry constituents, including horsemen and other racetracks; inability to successfully focus on market access and retail operations for our TwinSpires Sports and Casino business and effectively compete; online security risk, including cyber-security breaches, or loss or misuse of our stored information as a result of a breach; reliance on our technology services and catastrophic events and system failures disrupting our operations; inability to identify and / or complete, or fully realize the benefits of acquisitions, divestitures, development of new venues or the expansion of existing facilities on time, on budget, or as planned; difficulty in integrating recent or future acquisitions into our operations; cost overruns and other uncertainties associated with the development of new venues and the expansion of existing facilities; general risks related to real estate ownership and significant expenditures, including risks related to environmental liabilities; personal injury litigation related to injuries occurring at our racetracks; compliance with the Foreign Corrupt Practices Act or other similar laws and regulations, or applicable anti-money laundering regulations; payment-related risks, such as risk associated with fraudulent credit card or debit card use; work stoppages and labor problems; risks related to pending or future legal proceedings and other actions; highly regulated operations and changes in the regulatory environment could adversely affect our business; restrictions in our debt facilities limiting our flexibility to operate our business; failure to comply with the financial ratios and other covenants in our debt facilities and other indebtedness; increases to interest rates (due to inflation or otherwise), disruption in the credit markets or changes to our credit ratings may adversely affect our business; increase in our insurance costs, or inability to obtain similar insurance coverage in the future, and any inability to recover under our insurance policies for damages sustained at our properties in the event of inclement weather and casualty events; and other factors described under the heading “Risk Factors” in our most recent Annual Report on Form 10-K and other filings we make with the Securities and Exchange Commission.

We do not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

     
Investor Contact: Phil Forbis   Media Contact: Tonya Abeln
(502) 394-1094   (502) 386-1742
[email protected]   [email protected]
     
     
     
     
     
     

 



Posted on

HII Christens Virginia-Class Attack Submarine Massachusetts (SSN 798)

NEWPORT NEWS, Va., May 06, 2023 (GLOBE NEWSWIRE) — HII (NYSE: HII) today christened the Virginia-class submarine Massachusetts (SSN 798) at the company’s Newport News Shipbuilding division.

“Shipbuilding is a noble calling, and you can see our pride in the craftsmanship before you,” NNS President Jennifer Boykin said. “When Massachusetts joins the fleet, she will be the latest in innovation and power, forging ahead in defense of our freedom, just like Paul Revere on his famous midnight ride. As SSN 798 supports the Navy’s critical missions around the world, she will carry with her the patriotism of her shipbuilders.”

Sheryl Sandberg, founder and chair of the Sandberg Goldberg Bernthal Family Foundation, and former chief operating officer of Meta (formerly Facebook), serves as the ship’s sponsor. Sandberg performed the traditional honor of breaking a bottle of American sparkling wine across the submarine’s bow during the ceremony.

Photos accompanying this release are available at: https://hii.com/news/hii-christens-virginia-class-attack-submarine-massachusetts-ssn-798.

“I was raised to be deeply grateful for our freedom and all those who risk their lives to defend it,” Sandberg said. “So it was an honor when then Secretary of the Navy Ray Mabus asked me to sponsor Massachusetts eight years ago. I couldn’t be more excited to be in Newport News to celebrate this boat with the shipbuilders who have worked so hard to bring her to life. Today is more than just a christening of a vessel. It is also a celebration of progress. This is one of the first submarines intentionally built to allow both men and women to serve and it will make our military stronger. It is an honor to christen Massachusetts and spend the day with service members, shipbuilders and their families. They are a living legacy of all that America represents.”

The ceremony took place outside of Module Outfitting Facility at NNS and was attended by more than 2,000 guests, including NNS employees who are building Massachusetts, members of the submarine’s crew, Navy personnel and other government officials.

Under Secretary of the Navy Erik Raven provided the keynote address.

“From design, to delivery, to employment, each person here is making their vital contribution to maintaining our nation’s maritime dominance and the freedom that we all cherish,” Raven told the crowd. “We are able to deploy exquisite capabilities across the globe in great part to our dedicated shipbuilders. These talented women and men are able to turn raw steel into the world’s most sophisticated undersea capabilities.”

Massachusetts is the 25th Virginia-class submarine and the 12th to be delivered by NNS.

“The crew and I are excited to share in this historic event with our sponsor, the shipbuilder, and all our families,” said Cmdr. Mike Siedsma, commanding officer of the pre-commissioning unit. “We look forward to operating Massachusetts in support of our nation’s defense. We are honored to establish the ‘Iron Patriots’ legacy as an enemy to tyrants.”

NNS is one of only two shipyards capable of designing and building nuclear-powered submarines for the U.S. Navy. The advanced capabilities of Virginia-class submarines increase firepower, maneuverability and stealth.

A video of the ceremony, along with additional information on Massachusetts, Sandberg and the Virginia-class submarine program, can be found at: www.HII.com/SSN798

About HII 
HII is a global, all-domain defense provider. HII’s mission is to deliver the world’s most powerful ships and all-domain solutions in service of the nation, creating the advantage for our customers to protect peace and freedom around the world.

As the nation’s largest military shipbuilder, and with a more than 135-year history of advancing U.S. national security, HII delivers critical capabilities extending from ships to unmanned systems, cyber, ISR, AI/ML and synthetic training. Headquartered in Virginia, HII’s workforce is 43,000 strong. For more information, visit:

Contact:

Todd Corillo
[email protected]
(757) 688-3220

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/69b2c8e5-a1c2-4db7-bcdb-0b01acd76ec1

 



Posted on

New Head-to-Head Data ShowClareon Monofocal IOLs and TECNIS Eyhance Monofocal IOLs Provide Similar Range of Vision

New Head-to-Head Data ShowClareon Monofocal IOLs and TECNIS Eyhance Monofocal IOLs Provide Similar Range of Vision

  • An investigator led, non-interventional study evaluated the performance of two monofocal intraocular lenses (IOLs) in 620 eyes of 310 cataract patients in the U.S.1
  • Clareon monofocal IOL provides excellent distance vision, and intermediate vision that is non-inferior to TECNIS Eyhance* monofocal IOL1,2
  • The full Clareon Collection also offers surgeons clinically-proven extended depth of focus and presbyopia-correcting IOL options for patients desiring extended range of vision from cataract surgery3

FORT WORTH, Texas–(BUSINESS WIRE)–
Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced results from a new study presented at the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting taking place in San Diego, CA (May 5-8). The investigator-initiated study** led by J. Morgan Micheletti, M.D., demonstrated that Clareon® and Eyhance* monofocal IOLs provide similar range of vision, including distance and intermediate visual acuity.1

“The Eyhance monofocal IOL was introduced into our practice as a next-generation IOL offering to slightly extend the range of vision for our patients undergoing cataract surgery. However, we observed that our patients’ postoperative intermediate visual outcomes did not consistently demonstrate discernible improvements over other monofocal IOLs,” said Dr. Micheletti, Director of Research at Berkeley Eye Center. “In order to explore this further, we decided to look at real-world evidence by prospectively evaluating the vision of patients who had previously been implanted with bilateral Clareon monofocal IOLs or Eyhance IOLs. Given that our study of 310 patients (620 eyes) did not find a clinically significant difference between Clareon and Eyhance IOLs in terms of intermediate vision, this study adds to the growing body of data that raises questions about the scientific validity of the “monofocal plus” terminology at this point in time.”

The non-interventional, comparative study, aimed to evaluate visual outcomes in patients implanted with bilateral Clareon monofocal IOLs versus bilateral Eyhance monofocal/toric IOLs. The study evaluated 620 eyes of 310 patients (155 Clareon and 155 Eyhance) who had undergone successful, uncomplicated cataract surgery at least three months prior and had post-operative best-corrected distance visual acuity of 20/25 or better after cataract removal.1

Additional study findings include:1

  • Best-corrected distance acuity in eyes implanted with Clareon (0.01 logMAR) was similar to best-corrected distance acuity with Eyhance (0.02 logMAR).

  • Distance-corrected intermediate acuity was similar in both groups (Eyhance vs Clareon) with only a 2.5 letter mean difference.

  • The binocular defocus curves were extremely similar from +1.00 D to -3.00 D further demonstrating similar range of vision for both monofocal IOLs.

“At Alcon, research is the foundation for how we improve lives, and it goes beyond R&D—we also support real-world studies after our products move to market,” said Jim Di Filippo, Vice President and General Manager, US Surgical Franchise at Alcon. “We’re extremely proud of the innovation behind Clareon, our latest IOL material, which has now been implanted in more than three million people worldwide—and delivers on our promise of exceptional clarity with the real-world outcomes doctors and patients expect from Alcon.”

The FDA has specific standards for what constitutes an extended depth of focus (EDOF) lens, based on four criteria from the American National Standards Institute (ANSI).4 Eyhance monofocal IOLs and Clareon monofocal IOLs do not meet these criteria. The Clareon Vivity® IOL is the only available non-diffractive IOL that has received this FDA EDOF designation—offering patients excellent distance, excellent intermediate and functional near vision, with low incidence of visual disturbances.3

For information on the Clareon Collection of IOLs, please visit ClareonIOL.com.

About Clareon® IOLs and Delivery Systems

The family of Clareon® intraocular lenses (IOLs) includes the Clareon® Aspheric Hydrophobic Acrylic and Clareon® Aspheric Toric IOLs, the Clareon® PanOptix® Trifocal Hydrophobic IOL, Clareon PanOptix® Toric, Clareon Vivity® Extended Vision Hydrophobic Posterior Chamber IOL and Clareon® Vivity® Toric IOLs. Each of these IOLs is indicated for visual correction of aphakia in adult patients following cataract surgery. In addition, the Clareon® Toric IOLs are indicated to correct pre-existing corneal astigmatism at the time of cataract surgery. The Clareon® PanOptix® lens mitigates the effects of presbyopia by providing improved intermediate and near visual acuity while maintaining comparable distance visual acuity with a reduced need for eyeglasses, compared to a monofocal IOL. The Clareon® Vivity® lens mitigates the effects of presbyopia by providing an extended depth of focus. Compared to an aspheric monofocal IOL, the lens provides improved intermediate and near visual acuity while maintaining comparable distance visual acuity. All of these IOLs are intended for placement in the capsular bag. Careful preoperative evaluation and sound clinical judgment should be used by the surgeon to decide the risk/benefit ratio before implanting any IOL in a patient with any of the conditions described in the Directions for Use that accompany each IOL. Prior to surgery, physicians should provide prospective patients with a copy of the Patient Information Brochure available from Alcon, informing them of possible risks and benefits associated with these IOLs. Reference the Directions for Use labelling for each IOL for a complete listing of indications, warnings and precautions.

About Alcon

Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people’s lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 25,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care. Learn more at www.alcon.com.

*Trademarks are the property of their respective owners

**This investigator-initiated study was supported by Alcon

References

  1. Micheletti JM, Duncan N, Hall B. Head-to-Head Comparison of Intermediate Vision of Two Monofocal Intraocular Lenses. Presented at the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting; May 5-8, 2023; San Diego, CA, USA.

  2. Clareon IOL Aspheric Hydrophobic Acrylic IOL with the AutonoMe Directions for Use.

  3. Clareon Vivity IOL Directions for Use.

  4. For Ophthalmics – Extended Depth of Focus Intraocular Lenses. American National Standard. 2018.

Connect with us on

Facebook

LinkedIn

Investor Relations

Allen Trang

+ 41 589 112 110 (Geneva)

+ 1 817 615 2789 (Fort Worth)

[email protected]

Media Relations

Steven Smith

+ 41 589 112 111 (Geneva)

+ 1 817 551 8057 (Fort Worth)

[email protected]

KEYWORDS: California Texas United States North America

INDUSTRY KEYWORDS: Medical Devices Health Surgery Research Science Optical

MEDIA:

Logo
Logo
Posted on

Deucrictibant Data Highlighted in Multiple Presentations at the C1-Inhibitor Deficiency and Angioedema Workshop

ZUG, Switzerland, May 06, 2023 (GLOBE NEWSWIRE) — Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced two oral presentations and three poster presentations highlighting data from non-clinical and clinical studies of deucrictibant at the 13th C1-inhibitor Deficiency and Angioedema Workshop, being held from May 4-7, 2023, in Budapest, Hungary.

“Today, two sequential presentations showed how PHVS416 (immediate-release deucrictibant capsules) provided symptom relief and resolution in the treatment of HAE attacks using the doses projected through the bradykinin challenge, our in vivo surrogate marker model,” said Peng Lu, M.D., Ph.D., Chief Medical Officer of Pharvaris. “The RAPIDe-1 study showed consistent and clinically meaningful results across all endpoints supporting the further development of PHVS416 as a potential on-demand therapy for HAE. We plan to leverage these findings to prepare for RAPIDe-3, our Phase 3 clinical study evaluating PHVS416 for the treatment of on-demand HAE attacks.”

Anne Lesage, Ph.D., Chief Early Development Officer of Pharvaris, added, “The outcomes of the cardiovascular assessments in non-clinical studies, combined with the data from our clinical studies to date, support the cardiovascular tolerability and safety profile of deucrictibant for the potential treatment of HAE and other bradykinin-mediated diseases with unmet need.”

Presentation details and key data highlights include:

Additionally, data were presented from an independent investigator-initiated trial (IIT) in the Netherlands evaluating deucrictibant as a prophylactic treatment for acquired C1-inhibitor deficiency. Pharvaris provided PHVS416 (immediate-release deucrictibant capsules) for this study. Details of the presentation were:

About RAPIDe-1

RAPIDe-1 is a Phase 2, double-blind, placebo-controlled, randomized, cross-over, dose-ranging trial of PHVS416 (immediate-release deucrictibant capsules) for the treatment of HAE type 1 and type 2 (HAE-1/2) attacks. The trial enrolled participants in Canada, Europe, Israel, the United Kingdom, and the United States. Eligible participants were between the ages of 18 and 75 years, diagnosed with HAE type I or II and experienced three or more attacks in the last four months or two or more attacks in the last two months prior to screening. Seventy-four participants were enrolled and 62 of them experienced 147 qualifying HAE attacks that were treated with double-blinded study drug (either placebo or PHVS416 10, 20, or 30 mg doses).

About PHVS416 (immediate-release deucrictibant capsules)

PHVS416 (immediate-release deucrictibant capsules) is an investigational medicine intended to treat acute attacks of hereditary angioedema (HAE) containing deucrictibant, a highly potent, specific, and orally bioavailable competitive antagonist of the bradykinin B2 receptor. Pharvaris aims to develop this formulation to provide rapid and reliable symptom relief, through rapid exposure of attack-mitigating therapy in a convenient, small oral dosage form. PHVS416 is currently in Phase 2 clinical development outside the U.S. for the on-demand and proof-of-concept prophylactic treatment of HAE.

About PHVS719 (extended-release deucrictibant tablets)

PHVS719 (extended-release deucrictibant tablets) is an investigational medicine intended to prevent attacks of hereditary angioedema (HAE) containing deucrictibant, a highly potent, specific, and orally bioavailable competitive antagonist of the bradykinin B2 receptor. Pharvaris is developing this formulation to provide sustained exposure of attack-preventing medicine in a convenient, small oral dosage form. PHVS719 is currently in Phase 1 clinical development for the prophylactic treatment of HAE. In healthy volunteers, a single dose of PHVS719 was well tolerated with an extended-release profile supporting once-daily dosing.

About Pharvaris

Building on its deep-seated roots in HAE, Pharvaris is a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent HAE attacks. By directly targeting this clinically proven therapeutic target with novel small molecules, the Pharvaris team aspires to offer people with all sub-types of HAE safe, effective, and convenient alternatives to treat attacks, both on-demand and prophylactically. The company brings together the best talent in the industry with deep expertise in rare diseases and HAE. For more information, visit https://pharvaris.com/.

Forward-Looking Statements

This press release contains certain forward-looking statements that involve substantial risks and uncertainties. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements relating to our future plans, studies and trials, and any statements containing the words “believe,” “anticipate,” “expect,” “estimate,” “may,” “could,” “should,” “would,” “will,” “intend” and similar expressions. These forward-looking statements are based on management’s current expectations, are neither promises nor guarantees, and involve known and unknown risks, uncertainties and other important factors that may cause Pharvaris’ actual results, performance or achievements to be materially different from its expectations expressed or implied by the forward-looking statements. Such risks include but are not limited to the following: uncertainty in the outcome of our interactions with regulatory authorities, including the FDA with respect to the clinical holds on deucrictibant clinical trials in the U.S.; the expected timing, progress, or success of our clinical development programs, especially for PHVS416 and PHVS719, which are in mid-stage global clinical trials and are currently on hold in the U.S. as a result of the clinical holds; risks arising from epidemic diseases, such as the COVID-19 pandemic, which may adversely impact our business, nonclinical studies, and clinical trials; the expected timing and results of the rodent toxicology study; the timing of regulatory approvals; the value of our ordinary shares; the timing, costs and other limitations involved in obtaining regulatory approval for our product candidates PHVS416 and PHVS719, or any other product candidate that we may develop in the future; our ability to establish commercial capabilities or enter into agreements with third parties to market, sell, and distribute our product candidates; our ability to compete in the pharmaceutical industry and with competitive generic products; our ability to market, commercialize and achieve market acceptance for our product candidates; our ability to raise capital when needed and on acceptable terms; regulatory developments in the United States, the European Union and other jurisdictions; our ability to protect our intellectual property and know-how and operate our business without infringing the intellectual property rights or regulatory exclusivity of others; our ability to manage negative consequences from changes in applicable laws and regulations, including tax laws, our ability to successfully remediate the material weaknesses in our internal control over financial reporting and to maintain an effective system of internal control over financial reporting; changes and uncertainty in general market, political and economic conditions, including as a result of inflation and the current conflict between Russia and Ukraine; and the other factors described under the headings “Cautionary Statement Regarding Forward-Looking Statements” and “Item 3. Key Information—D. Risk Factors” in our Annual Report on Form 20-F and other periodic filings with the Securities and Exchange Commission.

These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. While Pharvaris may elect to update such forward-looking statements at some point in the future, Pharvaris disclaims any obligation to do so, even if subsequent events cause its views to change. These forward-looking statements should not be relied upon as representing Pharvaris’ views as of any date subsequent to the date of this press release.



Contact
Maggie Beller
Head of Public Relations and Communications
[email protected]

Posted on

Sight Sciences Announces 12-month Results from the First Minimally Invasive Glaucoma Surgery (MIGS) Comparative Analysis of Real-World Data (RWD) from the American Academy of Ophthalmology IRIS® Registry

Patients undergoing procedures enabled with OMNI® Surgical System technology experienced a greater average reduction in IOP-lowering medication usage compared to other MIGS procedures or cataract surgery alone

MENLO PARK, Calif., May 06, 2023 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative technology that enables procedures intended to improve patients’ lives, today announced the results from a 12-month retrospective sub-analysis of IOP-lowering medication use following the three most commonly performed, FDA approved (or cleared) MIGS procedures in patients with mild stage glaucoma. Analysis included 16,789 patients in 4 different cohorts: 1) procedures enabled by OMNI® Surgical System technology in combination with cataract 2) iStent Inject® in combination with cataract 3) Hydrus® in combination with cataract or 4) cataract surgery alone.

The study titled, “A Clinical Registry Study of Glaucoma Medication Use in Patients with Mild Glaucoma Severity After MIGS,” will be presented tomorrow, May 7, by Michael Mbagwu, MD, Adjunct Clinical Instructor of Ophthalmology at Stanford University School of Medicine and Senior Medical Director of Verana Health, during the American Society of Cataract and Refractive Surgery annual meeting in San Diego, California.

Analysis of medical records of 16,789 mild glaucoma patients in the American Academy of Ophthalmology (Academy) IRIS® Registry (Intelligent Research in Sight), one of the largest specialty society clinical data registries in all of medicine, showed that patients in the OMNI technology cohort experienced the greatest average medication reduction with a mean reduction from baseline of 1.01 glaucoma medications at 12 months post-operatively. This was a statistically significantly greater medication reduction (p<0.001) when compared to the medication reductions observed for the iStent Inject® in combination with cataract surgery as well as cataract surgery alone¹. The retrospective analysis was performed in partnership with Verana Health, the exclusive end-to-end data curation and analytics partner for the Academy’s IRIS Registry.

“We hope the real-world clinical data we are presenting at the ASCRS annual meeting will encourage stakeholders to reevaluate treatment paradigms for glaucoma patients – whether it be patients seeking to reduce their daily medication burden, surgeons looking for clinically effective options, or payors interested in cost-effective treatments,” said Dr. Mbagwu. “Given the limitations and challenges inherent in topical IOP-lowering medications, such as long-term adherence and adverse events that contribute towards discontinuation, the meaningful reduction in medication usage for patients with mild glaucoma with the OMNI technology is significant. As physicians, we should be open to tailoring treatment options in a patient-specific way, including offering MIGS as a means for both IOP and medication reduction. This sub-analysis shows differential outcomes for the most commonly used MIGS in the real-world setting and should inform future conversations.”

The collaboration between Sight Sciences and Verana Health reviewed real-world clinical outcomes data from MIGS devices and procedures within the IRIS Registry database from 2018-2020. The study’s primary endpoint evaluated and compared IOP and medication reduction among FDA-approved or cleared MIGS used in combination with cataract surgery as well as cataract procedures alone at pre-specified time intervals up to 24 months.

“This is the first large-scale comparative study leveraging the IRIS Registry with the most comprehensive MIGS dataset ever assembled using pharmacy claims data to understand glaucoma medication utilization, and tells a very compelling story in terms of how the most commonly used MIGS procedures perform in the real world. We believe such reliable, real world, and large-scale third party de-identified data from the Academy’s database will be very informative to MIGS decision-making going forward and we look forward to continuing to educate physicians and payors that outflow restorative procedures enabled by our technology can deliver meaningful and sustained reductions in intraocular pressure and medication use,” said Paul Badawi, co-founder and CEO of Sight Sciences. “We look forward to presenting additional data from this large-scale project at upcoming medical meetings and sharing the comprehensive data set in a leading peer-reviewed publication in 2023.”

The IRIS Registry is the first comprehensive eye disease clinical registry in the United States. Launched in 2014, it has amassed over 490 million billable patient visits and 79 million unique de-identified patients from nearly 56 electronic health records systems (EHRs) and more than 15,000 ophthalmologists and other eye care professionals across the U.S., as of April 1, 2023.

About Sight Sciences

Sight Sciences is an eyecare technology company focused on developing and commercializing innovative solutions intended to transform care and improve patients’ lives. Using minimally invasive or non-invasive approaches to target the underlying causes of the world’s most prevalent eye diseases, Sight Sciences seeks to create more effective treatment paradigms that enhance patient care and supplant conventional outdated approaches. The company’s current portfolio includes multiple technologies including the OMNI Surgical System, SION Surgical Instrument, and TearCare.

Visit SightSciences.com for more information.

About the OMNI Surgical System

The OMNI® Surgical System technology is a handheld, single-use therapeutic technology for minimally invasive glaucoma surgery (MIGS). OMNI technology enables surgeons to access 360 degrees and three primary points of resistance of an eye’s diseased conventional outflow pathway (trabecular meshwork, Schlemm’s canal, and collector channels) through a single clear corneal microincision.

OMNI’s FDA-cleared indication is for canaloplasty (the microcatheterization and viscodilation of Schlemm’s canal) followed by trabeculotomy (the cutting of trabecular meshwork) to reduce intraocular pressure in adult patients with primary open-angle glaucoma. OMNI has a CE Mark for the catheterization and transluminal viscodilation of Schlemm’s canal and the cutting of trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma.

OMNI should not be used in any situations where the iridocorneal angle is compromised or has been damaged since it may not be possible to visualize the angle or to properly pass the microcatheter. Do not use the OMNI in patients with angle recession; neovascular glaucoma; chronic angle closure; narrow-angle glaucoma; traumatic or malignant glaucoma; or narrow inlet canals with plateau iris or in quadrants with previous MIGS implants.

OMNI technology is protected by a global patent portfolio including 32 issued patents worldwide. OMNI is a registered trademark of Sight Sciences.

Visit www.OMNIsurgical.com for more information.

About Verana Health

Verana Health® is a digital health company elevating quality in real-world data. Verana Health operates an exclusive real-world data network of more than 20,000 healthcare providers (HCPs) and about 90 million de-identified patients, stemming from its strategic data partnerships with the American Academy of Ophthalmology®, American Academy of Neurology, and American Urological Association. Using its clinician-informed and artificial intelligence-enhanced VeraQ® population health data engine, Verana Health transforms structured and unstructured healthcare data into curated, disease-specific data modules, Qdata®. Verana Health’s Qdata helps power analytics solutions and software-as-a-service products for real-world evidence generation, clinical trials enablement, HCP quality reporting, and medical registry data management. Verana Health’s quality data and insights help drive progress in medicine to enhance the quality of care and quality of life for patients.

Visit www.veranahealth.com for more information.

© 2023 Sight Sciences. All rights reserved.

Glaucoma Media Contact

Carmen Caricchio
C2M Group
[email protected]

Investor contact

Philip Taylor
Gilmartin Group
415.937.5406
[email protected]

OM-2896-US.v1

__________________________________
¹ There was no statistical significance in the average medication reduction between Hydrus and Omni (ns, p=.131)